Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1431-1443

  Jhaveri, M ^a   Seal, B ^b   Pollack, Michael ^b   Wertz, D ^b  

^a sanofi aventis ^*

^b HEALTHCORE INC   (United States)

Author keywords

Cost; Economics; Insomnia; Predictive modeling

Indexed keywords

AMBIEN IR; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; INDIPLON; QUAZEPAM; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; INSOMNIA; LOW DRUG DOSE; MALE; MANAGED CARE; META ANALYSIS; SLEEP; SLEEP TIME; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; UNITED STATES;

ADOLESCENT; ADULT; ALGORITHMS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; FEMALE; FORECASTING; HEALTH CARE COSTS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 34347241309     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199619     Document Type: Article

References (52)

1. Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-62
2. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84
3. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med 1995;10:25-32
4. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42:225-32
5. Ustun T, Privett M, Lecrubier Y, et al. Form, frequency and burden of sleep problems in general health care: a report from the WHO Collaborative Study on Psychological Problems in General Health Care. European Psychiatry 1996;11(Suppl 1): 5-10s
6. Terzano M.G, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, Zolpidem and zaleplon. Drug Safety 2003;26:261-82
7. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111
8. Perlis ML, Smith LJ, Lyness JM, et al. Insomnia as a risk factor for onset of depression in the elderly. Behav Sleep Med 2006;4:104-13
9. Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manage Care 2006;12(Suppl 8):S214-20
10. Gooneratne NS, Gehrman PR, Nkwuo JE, et al. Consequences of comorbid insomnia symptoms and sleep-related breathing disorder in elderly subjects. Arch Intern Med 2006;166: 1732-8
11. NIH Statement Regarding the Treatment of Insomnia. Manifestations and management of chronic insomnia in adults. Sleep 2005;28:1049-57
12. Hatoum HT, Kong SX, Kania CM, et al. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 1998;14:629-37
13. Leger D, Guilleminault C, Bader G, et al. Medical and socioprofessional impact of insomnia. Sleep 2002;25:625-9
14. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354-8
15. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics 1996;10(Suppl 1):1-14
16. Stoller MK. Economic effects of insomnia. Clin Ther 1994;16:873-97
17. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):S386-93
18. Leger D, Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysomatic condition. Curr Med Res Opin 2005;21:1785-92
19. Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993;242:329-36
20. IMS Health. Commonly requested therapeutic class and product information (update February 2006). Available at: www. imshealth.com/ims/portal/front/ articleC/0,2777,6599_18731_ 77056778,00.html [Last accessed 28 March 2007]
21. Morin AK. Strategies for treating chronic insomnia. Am J Manag Care 2006;12:S230-45
22. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006;18:49-56
23. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care 2006;12:S246-52
24. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12:S221-9
25. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: upate of the recent evidence (1998-2004). Sleep 2666;29:1398-414
26. Botteman, Ozminkowski RJ, Wang S, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007;21: 319-34
27. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs. zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851-8
28. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and Zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology: Clinical and Experimental 1998;13:191-8
29. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249-60
30. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl 17):28-31
31. Morlock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of the National Ambulatory Medical Survey data, 1997-2002. Clin Ther 2006;28:1044-53
32. Roehrs T, Roth T. 'Hypnotic' prescription patterns in a large managed-care population. Sleep Med 2004;5:463-6
33. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406
34. Herrmann WM, Kubicki ST, Boden S, et al. Pilot controlled double-blind study of the hypnotic effects of Zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res 1993;6: 306-22
35. Monti JM, Monti D, Estevez F, et al. Sleep in patients with chronic primary insomnia during long-term Zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996;11:255-63
36. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg Zolpidem. Clin Neuropharmacol 1997;20:116-25
37. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating Zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9
38. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91
39. The Neurocrine Company. Phase III Chronic Insomnia (Indiplon-IR). Available at: www.neurocrine.com/pdf/ CurrentSlidePresentation.pdf (slide 31). [Last accessed 28 March 2007]
40. Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 2005;28:A228-9
41. Roth T, Zammit G, Jochelson P, et al. Efficacy and safety of indiplon-IR in adults with chronic insomnia characterized by prolonged nighttime awakenings with difficulty returning to sleep. American Psychiatric Association 2005 Annual Meeting; May 21-26, 2005; Atlanta, Georgia. Sleep 2005:Abstract NR683
42. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
43. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41-9
44. Culpepper L. Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin 2006;22:1257-68
45. Greene WH. Econometric Analysis. Upper Saddle River, N.J: Prentice Hall, 2000
46. Wooldridge JM. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press, 2002
47. Micromedex® Healthcare Series - Red Book Ready Price®. Greenwood Village, CO: Thompson Micromedex, updated periodically [Last accessed 31 May 2006]
48. Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1, 2000 to July 1, 2004. United States Census Bureau. Available at: www.census.gov/ popest/national/asrh/NC-EST2004-sa.html. [Last accessed 22 August 2006]
49. 2005 Sleep in America Poll. National Sleep Foundation, 2005. Washington DC. Available at: www.sleepfoundation.org [Last accessed 15, July 2006]
50. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United Status: results of the 1991 National Sleep Foundation Survey. Sleep 1999; 22(Suppl 2):S347-53
51. Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006;12:S214-20
52. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004;65(Suppl 8):13-19